Leap Therapeutics

Leap Therapeutics reported Phase 2 DeFianCe data for sirexatamab combined with bevacizumab and chemotherapy in advanced colorectal adenocarcinoma; the predefined primary endpoint of PFS in the intent-to-treat population was not met, with 9.2 vs. 8.3 months (HR 0.84). Exploratory biomarker analyses, however, show that patients with higher baseline DKK1 had greater PFS benefits versus control (top quartile 9.4 vs. 5.9 months). Sirexatamab was overall well tolerated, and the FDA had already granted the drug Fast Track status for DKK1-high metastatic colorectal cancer. » Altro su de.investing.com

Leap Therapeutics announced it will rebrand to Cypherpunk Technologies and begin trading under the ticker CYPH, shifting from biotech to a crypto treasury strategy focused on Zcash. The company used $50 million from a private placement led by Winklevoss Capital to purchase 203,775.27 ZEC at an average price of $245.37 per coin and said it aims to hold at least 5% of ZEC supply. The move spurred the stock to surge over 100% as Cypherpunk outlines plans to accumulate and support privacy-focused crypto assets. » Altro su finance.yahoo.com